Home / Business and Economy / eMed Secures $200M, Valued Over $2B for GLP-1 Management
eMed Secures $200M, Valued Over $2B for GLP-1 Management
26 Mar
Summary
- eMed received $200 million, valuing it over $2 billion.
- Company partners with employers to manage GLP-1 drug usage.
- Funding advances AI platform and a new healthcare payment model.
Telehealth company eMed announced on March 26, 2026, that it has raised $200 million in a series A funding round, achieving a valuation exceeding $2 billion. This significant investment was led by Aon Consulting, with notable participation from founding chief wellness officer Tom Brady and CEO Linda Yaccarino.
The proceeds are earmarked for the advancement of eMed's agentic AI platform. Additionally, the funds will strengthen the company's financial standing as it prepares to launch an innovative healthcare payment model aimed at reducing costs for employers.
eMed partners with employers and government payers to oversee the utilization of GLP-1 medications, a class of drugs for obesity and diabetes. The company aims to address the cost barriers that have limited broader insurance coverage for these treatments.
Founded in 2020, eMed initially gained recognition for its at-home COVID-19 tests during the pandemic. It has since expanded its focus to managing population health and controlling rising healthcare expenditures, particularly concerning expensive drug classes like GLP-1s.
